A Study on Optimizing HBeAg Seroconversion in HBeAg Positive CHB Patients With Combination or Sequential Treatment of Pegylated Interferon Alpha-2a and Entecavir

Trial Profile

A Study on Optimizing HBeAg Seroconversion in HBeAg Positive CHB Patients With Combination or Sequential Treatment of Pegylated Interferon Alpha-2a and Entecavir

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Mar 2016

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Entecavir
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Acronyms OSST
  • Sponsors Roche
  • Most Recent Events

    • 13 Nov 2012 Primary endpoint 'Seroconversion-rate' has been met.
    • 06 Jul 2012 Actual patient number changed from 134 to 200 as reported by ClinicalTrials.gov.
    • 18 Apr 2012 Actual patient number changed from 119 to 134 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top